Dr. Anjali Rohatgi, MD

Dr. Rohatgi practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Rohatgi's NPI, 1700267986, was assigned on June 14, 2015. Dr. Rohatgi graduated from Washington University School of Medicine in 2015. Dr. Rohatgi holds Missouri license 2021039559.

Dr. Rohatgi's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Rohatgi also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Rohatgi's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Rohatgi is also affiliated with Missouri Baptist Medical Center. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Rohatgi to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rohatgi practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Rohatgi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Rohatgi is licensed in Missouri.

CMS data shows 1,156 Medicare services from Dr. Rohatgi across 16 procedure codes in 2024, for 222 Medicare patients. Medicare paid $37,850 for them.

CMS counts 222 Medicare patients who saw Dr. Rohatgi in 2024. The largest group is 65 to 74, with 106 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 10% are also on Medicaid. Their average risk score is 3.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rohatgi's median patient age at 72, with 60% women.

In 2024, Dr. Rohatgi wrote 1,302 Medicare Part D claims for 150 patients. 89% of them were for generic drugs. CMS names the drug for 1,025 of them, across 29 drugs with 11 or more claims each, at $799,763 in total drug cost. In 2023, CMS named 784 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Rohatgi for performance year 2024, reported as part of a group. Dr. Rohatgi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rohatgi as offering telehealth.

Dmand AI links 10 papers to Dr. Rohatgi, published from 2011 to 2025. 2021 was the busiest year, with 2. The most frequent topics are Alphavirus Infections, Chikungunya Fever and Chikungunya virus. Dr. Rohatgi's most frequent co-authors are Deborah J. Lenschow, MD, George Ansstas, MD and Siddhartha Harish Krishna Devarakonda, MD.

CMS Open Payments shows 10 general payments to Dr. Rohatgi from 6 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 87% of the total. Amgen Inc. paid the most, $4,116.

Dr. Rohatgi graduated from Washington University School of Medicine in 2015.